FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG).

Cancers (Basel) · 2025 · PMC12427567 · PMID 40940827

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

We found that mFOLFIRINOX was associated with significantly improved disease-free survival and a favorable trend toward better overall survival, independent of histological subtype.

also in 932 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.